Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03606174 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
A Phase 2 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT03606174 is a Phase 2 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 260 participants.
The verdict
NCT03606174, a Phase 2 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Enfortumab vedotin
- DRUG Sitravatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2018-09-11 |
| Est. Completion | 2022-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03606174
The ClinicalTrials.gov registry entry for NCT03606174 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03606174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03606174 about?
NCT03606174 is a clinical study titled "A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma". The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
What is the current status of trial NCT03606174?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2018-09-11. Estimated completion is 2022-08-22.
What interventions are being tested in trial NCT03606174?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Enfortumab vedotin (DRUG), Sitravatinib (DRUG).
Who is sponsoring clinical trial NCT03606174?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.